BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
Clinical - Phase I
Cellular Biomedicine Group (CBMG) Announces Positive Phase I Results From CAR-T CD30 Immuno-Oncology Clinical Development Program 5/22/2015
IRB Approves Additional Enrollment In Cellceutix (CTIX)'s Clinical Trial Of New Cancer Drug Candidate For Solid Tumors 5/22/2015
Stock Soars as bluebird bio (BLUE) Gives Sneak Peek at Promising Sickle Cell Data 5/21/2015
Johnson & Johnson (JNJ) Announced 10 New Approval Applications with $1 Billion Revenue Potential Each 5/21/2015
e-Therapeutics plc Release: Progress In ETS2101 Phase Ib Study 5/21/2015
Isarna Therapeutics Announces Orphan Drug Designation In The European Union For ISTH0036 To Treat Advanced-Stage Glaucoma 5/21/2015
EMD Serono, Inc. Release: Rebif (interferon beta-1a) Data At CMSC Annual Meeting Highlights Clinical And MRI Predictors For Long Term Outcomes 5/21/2015
ContraFect (CFRXU) Announces First Healthy Volunteer Dosed With CF-301 5/21/2015
Calithera Biosciences, Inc. (CALA) Reports Initial Phase I Data For CB-839 In Patients With Acute Leukemias 5/21/2015
Kite Pharma (KITE) Announces That The First Patient In Its Phase I/II Clinical Trial Has Been Treated With KTE-C19, Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, For Refractory Aggressive Non-Hodgkin's Lymphoma (NHL) 5/21/2015
RestorGenex Announces Data On The Effect Of RES-529 In Pulmonary Fibrosis Models 5/21/2015
Prothena (PRTA) Announces Presentation Of Clinical Data From The Ongoing Phase I/II NEOD001 Study And Systemic Amyloidosis Patient Survey Results At 20th Congress Of The European Hematology Association 5/21/2015
bluebird bio (BLUE) To Present Lentiglobin Clinical Data At 20th Congress Of European Hematology Association 5/21/2015
Oncolytics Biotech Inc. (ONC.TO) Announces Phase 1 Study In Pediatric Patients With Brain Tumors 5/19/2015
GlycoMimetics, Inc. (GLYC) Initiates Phase I/II Clinical Trial Of GMI-1271 As Potential Treatment For Acute Myeloid Leukemia In Combination With Chemotherapy 5/19/2015
GlycoMimetics, Inc. (GLYC) Initiates Phase I/II Clinical Trial Of GMI-1271 As Potential Treatment For Acute Myeloid Leukemia In Combination With Chemotherapy 5/19/2015
DURECT Corporation (DRRX) Announces Positive Results From DUR-928 Multi-Dose Phase 1 Study 5/18/2015
Agios (AGIO) Announces FDA Fast Track Designation Granted To AG-120 For Treatment Of Patients With Acute Myelogenous Leukemia With An IDH1 Mutation 5/18/2015
Idera Pharmaceuticals, Inc. (IDRA) Provides Development Update On IMO-9200, An Antagonist Of Toll-Like Receptors 5/18/2015
Portola Pharmaceuticals, Inc. Announces Upcoming Data Presentation On Dual Kinase Inhibitor Cerdulatinib At ASCO Annual Meeting 5/18/2015
Significant Progress For Pluristem Therapeutics (PSTI): PLX Cells Were Selected For European Medicines Agency's Adaptive Pathways Pilot Project 5/18/2015
AbGenomics Corporation Announces Initiation Of Phase-Ib/Iia Clinical Trial Of Neihulizumab (AbGn-168H) For The Treatment Of Steroid Refractory Acute GvHD (aGvHD) 5/18/2015
Fraunhofer ITEM: Successful Testing Of New Drug For Allergic Asthma 5/18/2015
Alnylam (ALNY) Files Clinical Trial Application (CTA) for ALN-AAT, An Investigational RNAi Therapeutic For The Treatment Of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (Alpha-1 Liver Disease) 5/18/2015
Genentech (RHHBY) Lung Cancer Treatments Shrink Tumors, Prolong Life 5/15/2015
TapImmune Inc. (TPIV) Release: Phase I Study In Ovarian & Breast Cancer Published In Abstracts Of 2015 ASCO Annual Meeting 5/15/2015
Genentech (RHHBY)’s Investigational Medicine Alectinib Shrank Tumors In Nearly Half Of People With Specific Type Of Lung Cancer 5/14/2015
SAGE Therapeutics Elated as Brain Seizure Drug Shows 77% Response Rate 5/14/2015
Novogen Limited (NVGN) Release: Anisina Confirmed As Effective Anti-Cancer Agent In Animal Studies 5/14/2015
VBL Therapeutics (VBLX) To Present Positive Phase I/II Data For VB-111 In Recurrent Platinum-Resistant Mullerian Cancer At ASCO Annual Meeting 5/14/2015
Immune Design Corporation (IMDZ) Announces Positive Data From Three Phase I Studies At The 2015 ASCO Annual Meeting 5/14/2015
StemCells (STEM) Announces Positive Top-Line Results Of Its Thoracic Spinal Cord Injury Phase I/II Study 5/14/2015
Astellas Pharma Inc. (ALPMY) Announces New Data In Advanced Prostate And Breast Cancers, Acute Myeloid Leukemia, And Lung And Renal Cancers To Be Presented At 2015 ASCO Annual Meeting 5/14/2015
Strategic Science & Technologies Announces Completion Of Its Phase 1 Clinical Trial For SST-6007, A First-In-Class Topical Sildenafil Cream, To Treat Female Sexual Arousal Disorder 5/14/2015
TopiVert Starts Phase I Clinical Trial In Ulcerative Colitis 5/14/2015
Dicerna (DRNA) Announces Expansion Of Ongoing DCR-MYC Phase 1 Study To Evaluate Safety And Efficacy In Patients With Advanced Pancreatic Neuroendocrine Tumors (PNETs) 5/14/2015
FDA Grants Orphan Drug Designation To GlycoMimetics, Inc. (GLYC)’ GMI-1271 For Treatment Of Acute Myleogenous Leukemia (AML) 5/14/2015
Heron Therapeutics, Inc. (APPA) Announces Positive Outcome From Meeting With FDA For HTX-019 5/14/2015
Biocryst Pharmaceuticals (BCRX) Announces Initiation Of A Phase I Clinical Trial Of BCX7353 For The Treatment Of Hereditary Angioedema 5/13/2015
Oxford University, GlaxoSmithKline (GSK) And Emergent BioSolutions (EBS) Announce Initiation Of A Prime Boost Study Of Ebola Vaccine Candidates 5/13/2015
Bavarian Nordic (BAVA.CO) Announces Presentation Of Preliminary Phase 1 Results For The Ebola Prime-Boost Vaccine Regimen Of MVA-BN Filo And Janssen Pharmaceutical's AdVac Technology 5/13/2015
Public Statement From EuroVacc Foundation And IDT Biologika, Switzerland, Germany, May 13, 2015 5/13/2015
Inovio Pharmaceuticals (INO) Initiates Clinical Trial With DNA Immunotherapies To Prevent And Treat Ebola 5/12/2015
Dana-Farber Cancer Institute And Boston Children's Hospital Opens Phase I Trial Of Immunotherapy For Children With Relapsed Or Treatment-Resistant Leukemia 5/12/2015
Genelux Corporation To Present Posters Supporting Lead Oncolytic Viral Therapy GL-ONC1 At ASCO Annual Meeting 2015 5/12/2015
BEAT BioTherapeutics To Present New Data Supporting The Effectiveness Of BB-R12 In Treating Heart Failure 5/12/2015
ViaCyte, Inc. (Formerly Known as Novocell, Inc.) To Present At Cavendish Global Health Impact Forum 5/11/2015
Heat Biologics Announces Initiation Of Phase Ib Trial Of Viagenpumatucel-L (HS-110) In Non-Small Cell Lung Cancer (NSCLC) 5/11/2015
Jazz Pharmaceuticals (JAZZ) And Concert Pharmaceuticals Provide JZP-386 Program Update 5/8/2015
Mologen AG (MOLGF.PK): Aarhus University Hospital Initiates MGN1703 Study In HIV Patients 5/8/2015
TetraLogic Pharmaceuticals (TLOG)’s New IPO Takes A Hit As Company Halts Hepatitis B Trial 5/7/2015
Retrophin (RTRX) Receives FDA Orphan Drug Designation For RE-024 For The Treatment Of Pantothenate Kinase-Associated Neurodegeneration 5/6/2015
Tyrogenex, Inc. Presents Phase I Study Of X-82 For Wet AMD At The Annual Meeting Of The Association for Research in Vision & Ophthalmology 5/6/2015
MabVax Therapeutics, Inc.' Human Antibody Clinical Development Candidate HuMab 5B1 Successfully Clears Important Early Toxicology Testing 5/5/2015
ZIOPHARM Oncology, Inc. (ZIOP.OB) Announces Initiation Of Phase I Study Of Ad-RTS-IL-12 Gene Therapy In Patients With Brain Cancer 5/5/2015
Kineta Inc. Announces Promising Top-Line Clinical Results For Dalazatide; Target Implicated In Broad Array Of Autoimmune Diseases 5/5/2015
Arrowhead Research Corporation (ARWR) Completes Dosing Healthy Volunteers And Initiates Transition To Patients In Phase 1 Study Of ARC-AAT 5/5/2015
CytRx Corporation (CYTR) Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage And Improved Quality Of Life In Chemotherapy Resistant Cancers 5/4/2015
Aeolus Pharmaceuticals Inc. (AOLS.OB) Announces Complete Results From Successful Study Showing AEOL 10150 Doubles Survival Rate Following Lung Damage Caused By Acute Radiation Exposure 5/4/2015
GliaCure Initiates Phase 1b Dosing In Alzheimer's Patients 5/4/2015
STEM CELLS Translational Medicine Release: Clinical Trial Moves Stem Cell Therapy For ALS Patients One Step Closer To Reality 5/4/2015
Drawbridge Pharmaceuticals Moves Phaxan Forward 5/4/2015
Basilea Pharmaceutica (BSLN.SW) Reports Start Of First-In-Human Phase I Oncology Study With Oral Panraf Kinase Inhibitor 5/4/2015
Sorrento Therapeutics, Inc. Shows Off Positive TRIBECA Registrational Study Results 5/4/2015
Retrophin (RTRX) Announces FDA Review Of IND For RE-024 And Clearance To Proceed With Phase 1 Clinical Study In Healthy Adult Volunteers 5/1/2015
greenovation Biotech GmbH Filed Phase I Clinical Trial Application For Its moss-aGal Compound Intended For Treatment Of Patients Suffering From Fabry Disease 5/1/2015
Lycera Initiates Phase 1 Clinical Trial Of LYC-30937, A First-In-Class Atpase Modulator For Inflammatory Bowel Disease 4/30/2015
Arno Therapeutics Receives European Orphan Drug Designation For AR-12 To Treat Two Infectious Diseases 4/30/2015
The Myelin Repair Foundation And NIH Initiate Clinical Studies Of Guanabenz For Treatment Of Multiple Sclerosis 4/30/2015
ImmunoGen (IMGN) Has Good News, Bad News as Sanofi (SAN.PA) SAAR3419 Deal Falls Apart and Ovarian Cancer Treatment Moves Forward 4/29/2015
Ascendis Pharma A/S Announces Results Of Phase 1 Study Of Transcon Treprostinil 4/29/2015
Arena Pharmaceuticals, Inc. (ARNA) Reports Favorable Results From Phase 1 Single-Ascending Dose Clinical Trial Of APD371 4/29/2015
Benitec Biopharma Doses Fifth Patient And Initiates Additional Trial Site For Hepatitis C Trial 4/29/2015
Celsion Corporation (CLSN) Expands Clinical Development Plan For GEN-1 IL-12 Immunotherapy Program In Ovarian Cancer 4/29/2015
ContraFect (CFRXU) Announces Commencement Of Phase 1 Clinical Trial Of Cf-301 For Staph Bloodstream Infections, Including MRSA 4/29/2015
Constellation Pharmaceuticals Initiates Clinical Development Of CPI-1205, A Novel Inhibitor Of EZH2, In Patients With Lymphoma 4/28/2015
PTC Therapeutics (PTCT)' Cancer Stem Cell Program Targeting BMI1 Enters Phase 1 4/28/2015
aTyr Pharma Receives U.S. FDA Orphan Designation For Resolaris 4/27/2015
Aratana Therapeutics (PETX) Comments On ADXS31-164 (AT-014) Study Data Presented During Poster Session At The AACR Annual Meeting 2015 4/27/2015
ZIOPHARM, Inc. Announces Initiation of Phase 1b/2 Study of Ad-RTS-hIL-12 Gene Therapy in Patients With Locally Advanced or Metastatic Breast Cancer 4/27/2015
EXCLUSIVE: Jounce CEO Says Funding Aims for Trials Next Year, Will Hire 10 4/27/2015
GW Pharmaceuticals (GWPH) Receives Orphan Drug Designation From FDA For Cannabidiol For The Treatment Of Neonatal Hypoxic-Ischemic Encephalopathy 4/24/2015
Gilead (GILD)’s Hepatitis C Combo Shows Cure Rate of 93% At Six Weeks, Fails at Four 4/23/2015
Merck & Co. (MRK)'s Keytruda Effective Against Three Cancers 4/23/2015
Tisch MS Research Center Of New York Reports Early Improvement In Stem Cell Trial 4/23/2015
INSYS Therapeutics Commences Dosing In Phase 1/2 Safety And Pharmacokinetic Study Of Cannabidiol Oral Solution In Pediatric Epilepsy Patients 4/23/2015
Nordic Nanovector: Results Of Phase 1 Study Of Betalutin In Patients With Non-Hodgkin Lymphoma To Be Presented At The International Conference On Malignant Lymphoma 4/23/2015
Strategia Therapeutics Initiates A Phase 1/2a Clinical Trial Of The Anti-Cancer Agent E6201 In Patients With Advanced Hematologic Malignancies 4/22/2015
SolaranRx’s SRX-1177 Receives FDA Orphan Drug Designation As Malignant Melanoma Treatment 4/22/2015
Acorda Therapeutics (ACOR) Presents Data On First Clinical Study Of Remyelinating Antibody For Multiple Sclerosis At American Academy of Neurology Annual Meeting 4/22/2015
Verastem, Inc. (VSTM) Presents Encouraging Scientific Data On The Preferential Targeting Of Cancer Stem Cells At The 2015 AACR Annual Meeting 4/22/2015
Heat Biologics. To Present At The 2015 AACR Annual Meeting 4/22/2015
Triphase Accelerator Initiates Phase I Study Of Marizomib And Bevacizumab In Patients With Glioblastoma 4/22/2015
CAR-T Cell Companies Juno Therapeutics (JUNO), Kite Pharma (KITE), and ZIOPHARM, Inc. Get Stock Jitters on Disappointing Novartis AG (NVS) Trial News 4/22/2015
Inovio Pharmaceuticals (INO) And Roche (RHHBY) Initiate Clinical Trial For Inovio's DNA Immunotherapy To Treat Chronic Hepatitis B Infection 4/21/2015
Arno Therapeutics To Present Promising Data From Phase I Trial Of Onapristone At AACR Annual Meeting 2015 4/21/2015
Cortice Biosciences Announces Updated Results From A Phase 1/2 Clinical Trial Evaluating TPI 287 For Treatment Of Recurrent Glioblastoma 4/21/2015
New Data Show Rexahn Pharmaceuticals, Inc. (RNN)'s Supinoxin Decreases The Migration Of Human Triple Negative Breast Cancer Cells In A Metastatic Cancer Model 4/21/2015
Pfizer (PFE) Receives FDA Breakthrough Therapy Designation For XALKORI (crizotinib) For The Treatment Of Patients With ROS1-Positive Non-Small Cell Lung Cancer 4/21/2015
Merrimack (MACK) Announces Final Clinical Results For MM-302 Phase 1 Study Demonstrating Robust Activity In Heavily Pre-Treated Patients With HER2-Positive Metastatic Breast Cancer 4/21/2015
Juno Therapeutics (JUNO)' CAR T Cell Product Candidate JCAR017 Continues To Demonstrate Encouraging Outcomes In Pediatric Patients With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia 4/21/2015
ArQule, Inc. (ARQL) Announces Data Presentations With ARQ 087, Inhibitor Of FGFR, At AACR 4/21/2015
Merrimack (MACK) Release: First-in-Human Phase 1 Trial Of MM-141 Demonstrates Activity In Biomarker Positive Patients 4/21/2015
Nimbus Therapeutics Announces Initiation Of Clinical Studies For ACC Inhibitor 4/21/2015
Kineta Inc., University of Groningen Present New, Positive Data For Dalazatide In ANCA Vasculitis, An Orphan Disease 4/21/2015
Loxo Oncology (LOXO)'s LOXO-101 Demonstrates Encouraging Initial Results From Ongoing Phase Ia Dose Escalation Study 4/21/2015
MediciNova, Inc. Announces Positive Interim Safety Data From Clinical Trial Of MN-166 (Ibudilast) In ALS 4/21/2015
Pfizer (PFE) Snags FDA Breakthrough Therapy Tag for Xalkori 4/21/2015
AstraZeneca PLC (AZN)'s Experimental Lung Cancer Drug Delays Disease By More Than a Year 4/20/2015
Early Findings With KEYTRUDA (Pembrolizumab), Merck & Co. (MRK)’s Anti-PD-1 Therapy, In Patients With Advanced Pleural Mesothelioma Presented At American Association for Cancer Research Annual Meeting 4/20/2015
ChemoCentryx, Inc. (CCXI) Initiates Clinical Trial Of CCX872, Its Next-Generation, Orally Administered CCR2 Inhibitor, In Pancreatic Cancer 4/20/2015
Merck & Co. (MRK) Release: Treatment Of Advanced Non-Small Cell Lung Cancer (NSCLC) With Pembrolizumab Presented At AACR Annual Meeting And Published In The New England Journal of Medicine 4/20/2015
OncoCyte Corporation Announces Initial Data From Ongoing Clinical Study Of Collagen Type X As A Marker And Potential Diagnostic For Breast Cancer And Other Types Of Human Cancers 4/20/2015
Epizyme (EPZM) To Present Updated Data From Ongoing Phase 1 Dose Escalation Trial Of EZH2 Inhibitor EPZ-6438 At International Conference On Malignant Lymphoma 4/20/2015
PTC Therapeutics (PTCT) Phase 1 Data From Spinal Muscular Atrophy Program To Be Presented At The 2015 American Academy of Neurology Annual Meeting 4/20/2015
cCam Biotherapeutics Announces Initiation Of Phase 1 Trial Of CM-24, A Novel Immune Checkpoint Inhibitor For Cancer Immunotherapy 4/20/2015
Cardio3 Biosciences Announces Infusion Of First Patient In NKG2D Phase I Trial With No Short Term Adverse Events 4/20/2015
Bionomics Limited (BNO.AX) Showcases Oncology Drug Development Programs At 2015 American Association for Cancer Research Annual Meeting 4/17/2015
Cellectar Biosciences  (NVLT) Initiates Proof-Of-Concept Trial Of I-131-CLR1404 In Multiple Myeloma 4/16/2015
Avelas Biosciences Initiates Phase 1b Trial Of AVB-620 In Breast Cancer Patients 4/16/2015
EMD Serono Highlights Scientific Commitment To MS With Data Presented At The American Academy of Neurology Annual Meeting 4/16/2015
OncoMed Pharmaceuticals, Inc. (OMED) Presents Demcizumab Data From Phase 1b Clinical Trial In Non-Small Cell Lung Cancer Patients At The European Lung Cancer Conference 4/16/2015
Targacept (TRGT) Announces Negative Top-Line Results From Exploratory Study Of TC-6499 In Diabetic Gastroparesis 4/16/2015
Protalex, Inc. (PRTX) Announces Findings From Final Cohort Of U.S. Phase Ib Trial Of PRTX-100 In Active Rheumatoid Arthritis Patients 4/16/2015
Isarna Therapeutics Initiates First-In-Human Phase I Trial For ISTH0036 To Treat Advanced Glaucoma 4/16/2015
PsiOxus Therapeutics Limited Expands Clinical Studies For Immuno-Oncolytic Treatment Following Positive Response To Intravenous Delivery 4/16/2015
DelMar Pharmaceuticals Adds Fourth Clinical Trial Site In Phase I/II Multicenter Study Of VAL-083 For Recurrent Malignant Glioma 4/16/2015
SELLAS Life Sciences Group And Trojantec Ltd. Sign Exclusive License Agreement For Global Rights On Development And Commercialization Of Innovative TR-1 Anti-Cancer Antennapedia Technology 4/15/2015
Replicel Life Sciences Receives Approval To Conduct Clinical Trial For Patients With Chronic Achilles Tendinosis 4/15/2015
Hydra Biosciences, Inc. Receives Approval From Health Canada To Begin Phase 1 Trial For HX-100 4/14/2015
Prolong Pharmaceuticals Presents Data On Unique "Un-Sickling" In Vitro Activity Observed In Sickle Cell Investigational Drug SANGUINATE 4/14/2015
InnFocus FDA Phase One Enrollment Reaches 75 Patient Filing Milestone 4/13/2015
Upsher-Smith Laboratories To Present Data Evaluating The Long-Term Safety And Efficacy Of Qudexy XR (Topiramate) Extended-Release Capsules And Alternative Administration Techniques 4/13/2015
Cytori Therapeutics, Inc. (CYTX) Provides Twelve Month Data Update On Scleradec-I Trial 4/13/2015
Suven Life Sciences Ltd Initiated Multiple Ascending Dose (MAD) Studies In Phase 1 Clinical Trial For Their Investigational Compound SUVN-G3031 4/13/2015
Cell MedX Corp. (CMXC) Announces Additional Results Of Preliminary Analysis Of Metabolomic Assays In Phase 1 Pilot Clinical Trial 4/13/2015
Cardio3 BioSciences Enrolls First Patient in Phase I Trial For NKG2D CAR T-Cell 4/13/2015
FDA Modifies Partial Clinical Hold On Tekmira (TKMR)'s TKM-Ebola IND To Allow Multiple Dosing Of Healthy Volunteers 4/10/2015
Eisai Company (ESALY.PK) And Arena Pharmaceuticals, Inc. (ARNA) Complete Registrational Trials Of An Extended Release Formulation Of Lorcaserin 4/10/2015
Sihuan Pharmaceutical Starts US Trial Of Novel Cancer Drug 4/10/2015
MedImmune (AZN) Release: MEDI8897 Receives Fast Track Designation By The FDA For The Prevention Of Respiratory Disease Caused By RSV In Infants 4/9/2015
VBI Vaccines Announces New Data Supporting The Manufacture Of Its Prophylactic CMV Vaccine Candidate 4/9/2015
Advaxis, Inc. And Merck & Co. (MRK) Announce Initiation Of Enrollment In The Phase I/II Study Of ADXS-PSA In Combination With Anti-PD-1 Therapy, KEYTRUDA (Pembrolizumab), For The Treatment Of Advanced Prostate Cancer 4/8/2015
Prolong Pharmaceuticals' Flagship Product SANGUINATE Granted Orphan Drug Designation By The FDA 4/8/2015
Benitec, Inc. (BLT.AX) Provides Update On TT-034 Trial 4/7/2015
Targacept (TRGT) Abandons Nictoine Focus for Alzheimer's 4/6/2015
Celldex (CLDX) Announces Initiation Of Phase 1/2 Study Of Varlilumab In Combination With Ipilimumab And CDX-1401 In Metastatic Melanoma 4/6/2015
Curis, Inc. (CRIS) Announces Orphan Drug Designation For CUDC-907 In Diffuse Large B-Cell Lymphoma 4/6/2015
Immunomedics, Inc. (IMMU) To Provide Update On Sacituzumab Govitecan For The Therapy Of Solid Cancers 4/6/2015
Public Health Agency of Canada Release: Clinical Trials Prove Canada's VSV-EBOV Ebola Vaccine Safe And Effective 4/2/2015
Luye Pharma Reports Successful Phase I Trials Of Novel Anti-depressant 4/2/2015
Immune Design Corporation (IMDZ) Announces Positive Topline Data From Three Phase 1 Clinical Trials Of Immuno-Oncology Agents 4/1/2015
ESSA Pharma Announces Filing Of Investigational New Drug Application For EPI-506 4/1/2015
Sigma-Tau Pharmaceuticals Receives Orphan Drug Designation For STP-206 For Prevention Of Necrotizing Enterocolitis 4/1/2015
Idera Pharmaceuticals, Inc. (IDRA) Announces FDA Orphan Drug Designation For IMO-8400 For The Treatment Of Diffuse Large B-Cell Lymphoma 4/1/2015
Pharmacyclics (PCYC) Release: Solid Tumor Study Investigating Ibrutinib (IMBRUVICA) In Combination With Anti-PD-L1 Antibody (MEDI4736) Commences In Patients With Relapsed/Refractory Non-Small Cell Lung, Breast And Pancreatic Cancers 4/1/2015
Portage Biotech's Biohaven Announces Agreement With inVentiv Health (VTIV) 4/1/2015
Oramed Pharmaceuticals Inc. (ORMP) Enrolls First Patient In Its Glucose Clamp Study For Oral Insulin 4/1/2015
Dyax Corp. (DYAX) Announces Positive Results From Phase Ib Clinical Trial Of DX-2930 4/1/2015
Vaccinex, Inc. Provides An Update On Its VX15/2503 Phase 1 Clinical Trial In Multiple Sclerosis Patients 3/31/2015
PledPharma Presents Top-Line Results From Its PhaseIIb Study - Pledox(R) Reduces Nerve Damage In Conjunction With Chemotherapy By 43 Percent 3/30/2015
Lion Biotechnologies, Inc. Announces Positive Data From A TIL-Ipilimumab Combination Study In Melanoma 3/30/2015
Matinas BioPharma Completes Enrollment In First Human Trial Of MAT9001 3/30/2015
Novavax, Inc. (NVAX) Presents New Data From Non-Human Primate Ebola Challenge At The 7th International Symposium On Filoviruses 3/30/2015
DURECT Corporation (DRRX) Announces Initiation Of DUR-928 Multi-Dose Phase 1 Study 3/30/2015
PRA Health Sciences Expands Global Phase I Patient Strategy 3/30/2015
IntelliPharmaCeutics Reports Positive Topline Data Results From A Series Of Phase I Clinical Trials Of Its Abuse-Deterrent Rexista(TM) Oxycodone XR Tablets, And Files An IND For Rexista(TM) Oxycodone XR 3/30/2015
Calithera Biosciences, Inc. (CALA) Reports Fourth Quarter And Full Year 2014 Financial Results And Recent Highlights 3/27/2015
New Research Throws Cold Water on Biogen (BIIB)'s Recent Breakthrough 3/26/2015
Aridis Pharmaceuticals Commences Phase 1 Clinical Study Of Aerucin Monoclonal Antibody For Acute Pneumonia 3/26/2015
Transition Therapeutics Inc. (TTH.TO) Announces Results From Phase 1 AME & Renal Clearance Clinical Studies Of Neuropsychiatric Drug Candidate ELND005 3/26/2015
Essentialis Presents Results From The First Phase Of Clinical Study PC025 Evaluating DCCR In The Treatment Of Prader-Willi Syndrome At ACMG Annual Clinical Genetic Meeting 3/26/2015
Immune Design Corporation (IMDZ) Announces Treatment Of Patients With CMB305 Investigational Immuno-Oncology Agent 3/26/2015
Tianjin CanSino Biotechnology Release: China Ebola Vaccine Passes Phase I Test 3/26/2015
Zogenix (ZGNX) Announces First Patient Dosed In Relday Multi-Dose Clinical Study 3/26/2015
Vical Incorporated (VICL) Expands Infectious Disease Portfolio With Novel Antifungal From Astellas Pharma Inc. (ALPMY) 3/26/2015
MorphoSys AG And Celgene (CELG) Mutually Agree To End MOR202 Collaboration 3/26/2015
Aduro Biotech Receives Orphan Drug Designation For CRS-207 In Mesothelioma 3/26/2015
Cardio3 BioSciences Reports 2014 Financial And Operating Results 3/26/2015
Regulus Therapeutics, Inc. (RGLS) Receives Orphan Medicinal Product Designation From The European Commission (EC) For RG-012, A Microrna Therapeutic In Development For The Treatment Of Alport Syndrome 3/25/2015
Cellular Biomedicine Group (CBMG) Announces Phase I Results From CAR-T Immuno-Oncology Clinical Development Programs 3/25/2015
Therapure Innovations Receives FDA Approval To Proceed With A Phase 1 Clinical Trial Of The Targeted Liver Cancer Therapeutic TBI 302 3/25/2015
BioLineRx Ltd. Reports Successful Top-Line Safety And Efficacy Results For Novel Stem Cell Mobilization Treatment 3/25/2015
Tenth Cohort Completed In Cellceutix (CTIX) Clinical Trial Of Anti-Cancer Drug Kevetrin, No Adverse Events Reported 3/25/2015
Biogen (BIIB) Alzheimer's Drug Aducanumab Exceeds Expectations 3/25/2015
Biogen (BIIB) Drops Idec From Corporate Name, Expands Ambitions in Alzheimer's, ALS 3/24/2015
Prothena (PRTA) Soars on Positive Phase I Results Of Parkinson's Drug PRX002 3/24/2015
Relmada Therapeutics Receives Health Canada Clearance To Commence First Clinical Study For Novel Oral Formulations Of Buprenorphine 3/24/2015
GenVec Inc. (GNVC) Reports Fourth Quarter And 2014 Year-End Financial Results 3/24/2015
Eli Lilly (LLY),Novartis AG (NVS)-Backed Startup, Aeglea, Nabs $44 Million 3/23/2015
Biogen (BIIB) Slides For Alzheimer's Drug Wow Analysts, Set Up Fight for Eli Lilly (LLY) 3/23/2015
Isis Pharmaceuticals, Inc. (ISIS) Reports Positive Phase 1 Data on Isis-ANGPTL3Rx 3/23/2015
GenVec Inc. (GNVC) And TheraBiologics Form Collaboration To Develop Neural Stem Cell Mediated Cancer Therapies 3/23/2015
AB Science (AB.PA): Masitinib Receives Orphan Drug Designation For Amyotrophic Lateral Sclerosis From FDA 3/23/2015
Kamada Ltd. (KMDA) Awarded European Orphan Drug Designation For Its Alpha-1 Antitrypsin To Treat Graft-Versus-Host Disease 3/23/2015
Another Day, Another $456 Million Cancer Pact for Eli Lilly (LLY) 3/23/2015
Biogen Idec (BIIB) Presents Positive Interim Results From Phase 1B Study Of Investigational Alzheimer’s Disease Treatment Aducanumab (BIIB037) At 2015 AD/PD Conference 3/20/2015
Alzheon Announces Phase 1 Results Of ALZ-801, A First-in-Class Inhibitor Of Amyloid Formation And Neurotoxicity For Alzheimer’s Disease 3/20/2015
Synthetic Biologics, Inc. (SYN) Announces Positive Pharmacokinetics Data From Phase 1a And 1b Trials Of SYN-004 To Protect The Microbiome And Prevent C. difficile Infection 3/19/2015
HUYA Bioscience International Completes First Cohort In Phase 1 Clinical Trial Of HBI-8000 In Japan 3/19/2015